April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Local Rock Inhibition As A Novel IOP Lowering Strategy
Author Affiliations & Notes
  • Sarah Van de Velde
    Lab of Ophthalmology,
    KULeuven, Leuven, Belgium
  • Tine Van Bergen
    Lab of Ophthalmology,
    KULeuven, Leuven, Belgium
  • Sara Van de Veire
    Lab of Ophthalmology,
    KULeuven, Leuven, Belgium
  • Evelien Vandewalle
    Lab of Ophthalmology,
    KULeuven, Leuven, Belgium
  • Lieve Moons
    Derpartment of Biology,
    KULeuven, Leuven, Belgium
  • Ingeborg Stalmans
    Lab of Ophthalmology,
    KULeuven, Leuven, Belgium
  • Footnotes
    Commercial Relationships  Sarah Van de Velde, None; Tine Van Bergen, None; Sara Van de Veire, None; Evelien Vandewalle, None; Lieve Moons, None; Ingeborg Stalmans, AMAKEM NV Belgium (F)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 236. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sarah Van de Velde, Tine Van Bergen, Sara Van de Veire, Evelien Vandewalle, Lieve Moons, Ingeborg Stalmans; Local Rock Inhibition As A Novel IOP Lowering Strategy. Invest. Ophthalmol. Vis. Sci. 2011;52(14):236.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To elucidate a possible IOP lowering effect of a Rho-associated protein kinase (ROCK)-inhibitor in the rabbit eye.

Methods: : In all experiments, a ROCK inhibitor (AMA0076, 0,3 %; AMAKEM, Belgium) with local drug activity was used. The IOP lowering effect of AMA0076 was studied in 10 New Zealand rabbits. A first group of rabbits (n=5) received a single dose of topical AMA0076. Another group (n=5) received the compound topically three times daily. In both groups IOP was measured at different time points during three days.

Results: : Single dosing of AMA0076 resulted in a decrease in IOP starting 1h after administration and lasted for ±2,5h (on average 18%, p<0.05). Repeated topical administration (3x/day) of the compound resulted in a persistent decrease in IOP until the last measurement (on average 14%, p<0.05).

Conclusions: : Administration of the ROCK-inhibitor AMA0076 causes a reduction in IOP. This experiment was a proof of concept in which the IOP lowering effect of a single concentration of the compound was tested (0,3%). In the next phase of this experiment we will try to elucidate the optimal concentration and dosing regime. In the future, ROCK inhibition can open new perspectives for the treatment of glaucoma.

Keywords: intraocular pressure 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×